The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | PTCy based GvHD prophylaxis in myelofibrosis
Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, discusses the results of a retrospective analysis evaluating the outcomes of post-transplantation cyclophosphamide (PTCy) based graft-versus-host disease (GvHD) prophylaxis in patients undergoing allogeneic blood or marrow transplantation for myelofibrosis. Bone marrow transplantation using non-myeloablative conditioning and PTCy for graft-versus-host disease prophylaxis demonstrated comparable clinical outcomes as other studies in myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
